Biopharmaceutical company Aelis Farma (Euronext: AELIS) announced on Monday that it has received a second positive recommendation from the Independent Data Monitoring Committee (IDMC) following its review of the Phase 2b trial of AEF0217 in people with Down syndrome. The committee identified no safety concerns and recommended that the study continue without protocol modifications, while also supporting the potential initiation of a 12-month open-label extension.
The review covered safety data from 74 participants, including 54 who had completed at least 12 weeks of treatment. Of 42 treatment-emergent adverse events reported by 23 participants, 97.6% were mild. No serious or severe adverse events, treatment discontinuations or withdrawals due to adverse events were recorded. The findings also showed no clinically significant laboratory, cardiovascular or other safety signals.
The positive assessment extends to older adolescents aged 16-17, with adverse event rates comparable to those in adults, further supporting AEF0217's safety and tolerability profile.
The Phase 2b trial is progressing, with 108 of the planned 188 participants randomised as of 4 November 2026. Thirty-eight participants have completed the 24-week treatment period, with results expected by the end of 2027.
AEF0217 is a first-in-class candidate targeting cognitive impairments associated with Down syndrome and belongs to Aelis Farma's proprietary CB1 signalling-specific inhibitor (CB1-SSi) class.
Ascletis reports positive US Phase II topline results for ASC30 in diabetes
Edwards Lifesciences wins FDA approval for PASCAL Precision tricuspid repair system
Oracle partners AstraZeneca for AI-enabled healthcare innovation
Medtronic confirms separation of MiniMed
Philips-led EXIT-CVD consortium launches cardiovascular clinical studies across Europe
FDA accepts Bayer's application for KERENDIA in chronic kidney disease without diabetes
Genentech reports positive Phase II results for enicepatide in type 2 diabetes
Otsuka ICU Medical recalls 0.9% Sodium Chloride Injection
US FDA grants orphan drug designation for Lundbeck's asedebart
Seismic Pharmaceuticals enrols first patient in istaroxime global Phase 3 trial in cardiogenic shock
Ionis partner Novartis reports pelacarsen Phase 3 trial misses primary endpoint
Thryv Therapeutics licenses new class of SGK1 inhibitors, expanding into neurodegenerative disease
Lilly to acquire Merida Biosciences in USD2.875bn deal
GE HealthCare expands Vivid cardiovascular ultrasound portfolio with three new systems
Daiichi Sankyo data highlight real-world impact of bempedoic acid on cardiovascular risk